Answers are grounded in this paper and cite their sources.
Porcine reproductive and respiratory syndrome (PRRS) is a swine-specific immunosuppressive disease caused by PRRS virus (PRRSV). Because PRRSV mutates rapidly and recombines frequently, current vaccines provide insufficient cross-protection against emerging recombinant strains. From late 2023 to early 2024, several large-scale pig farms in Shaanxi and Anhui Provinces, China, experienced severe outbreaks marked by widespread maternal abortions and elevated stillbirth rates. In this study, a recombinant PRRSV strain (designated SS) was isolated from clinical samples. Phylogenetic analysis of its complete genome and GP5 gene classified strain SS into Lineage 1.8 (NADC30-like). Recombination analysis confirmed that the isolate is a natural recombinant between the NADC30 sublineage and a highly pathogenic PRRSV-like strain. The SS strain’s biological characteristics were assessed using piglet pathogenicity and pregnant sow challenge models. Results showed that it causes severe symptoms and mortality in piglets and sows, with higher virulence than most low-pathogenic NADC30-like strains. In the immunized pregnant sow model, sows given four doses of PRRSV modified live virus vaccine exhibited pyrexia and anorexia following SS challenge, despite having high antibody levels; the litter abortion rate reached 50%. Postchallenge antibody kinetics showed a transient decline followed by a sharp rise, indicating an anamnestic response and suggesting strong immune evasion. Overall, this research characterizes the pathogenicity of a novel NADC30-like recombinant in piglets and immunized sows, explores the immune evasion mechanisms of this sublineage, and offers insights to support epidemiological surveillance and targeted control of PRRSV.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: